Global Exporter & Bulk Supplier of Mozolieva 20 mg Injection

🌍 Introduction

Are you looking for a specialized and reliable global exporter for Mozolieva 20 mg Injection? At Ernest Oncology (the premier oncology division of Ernest Pharmaceutical Pvt. Ltd.), we are leaders in the international distribution of advanced hematology medications. We provide high-standard supply chain solutions for Plerixafor 20 mg injections to transplant centers, hospitals, and pharmaceutical wholesalers in the USA, UK, Australia, and South Africa.

🔬 1. Product Overview: Mozolieva 20 mg Injection

Mozolieva 20 mg Injection contains Plerixafor, a hematological agent used to enhance the mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent transplantation.

• Composition: Plerixafor 20 mg (in 1.2 mL solution)

• Therapeutic Class: Hematopoietic Stem Cell Mobilizer / CXCR4 Antagonist

• Formulation Type: Single-dose vial for Subcutaneous (SC) injection.

• Storage: Store at controlled room temperature ($20^\circ\text{C}$ to $25^\circ\text{C}$).

⚙️ 2. Mechanism of Action

Mozolieva works by temporarily "detaching" stem cells from the bone marrow:

• CXCR4 Antagonism: Plerixafor is a selective antagonist of the CXCR4 chemokine receptor.

• SDF-1 Connection: It blocks the binding of stromal cell-derived factor-1$\alpha$ (SDF-1$\alpha$) to the CXCR4 receptor.

• Mobilization: This blockade breaks the "anchor" holding hematopoietic stem cells in the bone marrow stroma, causing them to migrate into the peripheral blood.

• Apheresis Efficiency: By increasing the concentration of circulating stem cells, it significantly improves the success rate of stem cell collection (apheresis).

🏥 3. Therapeutic Indications

Mozolieva 20 mg Injection is clinically indicated for:

• Non-Hodgkin’s Lymphoma (NHL): In combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells for autologous transplantation.

• Multiple Myeloma (MM): To assist in the collection of sufficient stem cells in patients who have difficulty reaching target counts with G-CSF alone.

• Autologous Stem Cell Transplantation: Specifically targeted at patients where standard mobilization protocols have been insufficient.

⚠️ 4. Administration & Safety Guidelines

• Professional Administration: Must be administered only by healthcare professionals in a transplant or oncology setting.

• Timing: Typically administered approximately 11 hours prior to the initiation of apheresis, following 4 days of G-CSF treatment.

• Monitoring: Continuous monitoring for leukocytosis (high white blood cell count) and splenic enlargement/rupture is required.

• Renal Consideration: Dosage adjustment may be necessary for patients with renal impairment.